abstract |
The present invention relates to the use of miRNA as a pharmaceutical composition for the prevention or treatment of metabolic diseases. In the present invention, a candidate substance for metabolic diseases using miRNA was developed, and it was confirmed that it specifically down-regulated the RNA and protein levels at the target site of LXRβ. Therefore, the miRNAs miR-7, miR-18a or miR-18b discovered in the present invention can be useful for the treatment of metabolic diseases such as atherosclerosis, fatty liver, diabetes, hyperlipidemia, hypertension, angina pectoris and myocardial infarction . |